919 Spam-Free Article(s) Found
||Teva Pharmaceutical Industries Limited
Jun 12, 2017 - Teva Pharmaceutical Industries Ltd. said Monday it has launched a generic version of the cholesterol lowering medication Zetia.
Zetia, which contains the active ingredient ezetimibe, is a prescription medicine made by Merck (NYSE: MRK) used to lower levels of total cholesterol and low-density lipoprotein (LDL) cholesterol in the blood. Ezetimibe tablets are for patients who cannot control their cholesterol levels by diet and exercise alone. Teva said the product can be used by itself or with other…
Jun 12, 2017 - Teva Pharmaceutical Industries (TEVA +0.5%) launches its generic version of Merck's (MRK) cholesterol fighter ZETIA (ezetimibe) tablets in the U.S.According to IMS, the U.S. market is ~$2.7B.
Jun 09, 2017 - Foster City's Gilead Sciences won approval in 2012 of Truvada as the first drug to prevent the spread of the AIDS virus. What does it mean now that Teva Pharmaceutical Industries has won the OK to introduce a supposedly low-cost version of the drug?
Jun 09, 2017 - In the latest step toward remaking the company, Teva Pharmaceutical (NYSE:TEVA) will seek to overhaul its board by nominating four new directors.Among their first orders of business would be picking a
Jun 08, 2017 -
Teva Pharmaceutical Industries Ltd. TEVA announced that its experimental migraine prevention drug, fremanezumab, met all the primary and secondary endpoints in a second late-stage study.
Jun 06, 2017 - Teva's rough year continues to get worse. Is there light at the end of the tunnel?
Jun 05, 2017 - Regeneron Pharmaceuticals and partner Sanofi announced positive results related to its experimental candidate, REGN2810, a checkpoint inhibitor targeting PD-1 in patients with advanced cutaneous squamous cell carcinoma (CSCC).
Jun 01, 2017 - Teva Pharmaceutical Industries Limited (TEVA) announced positive top-line results from a phase III study (HALO), evaluating its pipeline candidate, fremanezumab (TEV-48125) for prevention of chronic migraine (CM).
Jun 01, 2017 - Read full story for latest details.
May 31, 2017 - A Phase 3 clinical trial, HALO, assessing Teva Pharmaceutical Industries' (TEVA +0.5%) fremanezumab for the prevention of migraine met all primary and secondary endpoints. Patients treated with the mo